diphenylamine has been researched along with Disease Models, Animal in 36 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 4 (11.11) | 18.7374 |
1990's | 2 (5.56) | 18.2507 |
2000's | 3 (8.33) | 29.6817 |
2010's | 24 (66.67) | 24.3611 |
2020's | 3 (8.33) | 2.80 |
Authors | Studies |
---|---|
Baeza-Garza, CD; Caldwell, ST; Coughlan, MT; De Blasio, MJ; Deo, M; Hartley, RC; Higgins, GC; Kiriazis, H; Krieg, T; Lindblom, R; Murphy, MP; Park, M; Prakoso, D; Ritchie, RH; Tate, M | 1 |
Bobyn, JD; Deo, N; Little, DG; Schindeler, A | 1 |
Abe, T; Aiba, S; Aoki, Y; Asao, A; Inoue, SI; Inoue-Shibui, A; Ishii, N; Katata, Y; Kobayashi, S; Kure, S; Niihori, T; Terui, H | 1 |
Chávez-Riveros, A; Hernández-Vázquez, E; Miranda, LD; Nieto-Camacho, A; Ramírez-Trinidad, Á | 1 |
Beer, AJ; Braren, R; Esposito, I; Fingerle, A; Gupta, A; Heid, I; Sengkwawoh-Lueong, S; Siveke, JT; Steiger, K; Teichmann, N; Trajkovic-Arsic, M; Wenzel, P; Wörner, C | 1 |
Andersen, NJ; Baker, LH; Boguslawski, EA; Dawes, MJ; Duesbery, NS; Dykema, KJ; Froman, RE; Furge, KA; Kamstock, DA; Kitchell, BE; Krivochenitser, RI; Nickoloff, BJ; Thomas, DG | 1 |
Barretina, J; Chitalia, R; Dodd, L; Dodd, RD; Eward, WC; Kirsch, DG; Ma, Y; Mito, JK; Sachdeva, M | 1 |
Andresen, CJ; Bagi, CM; Cirone, P; Eswaraka, JR; Lappin, PB | 1 |
Anderson, LK; Collins, MH; Greeley, AD; Halfond, AL; Keng, VW; Largaespada, DA; Moertel, CL; Powell, NM; Rahrmann, EP; Ratner, N; Rizvi, T; Watson, AL | 1 |
Jacobsen, JR; Klein, U; Linsell, MS; McKinnell, RM; Moran, EJ; Nodwell, MB; Pfeiffer, JW; Thomas, GR; Yu, C | 1 |
Carpenter, EC; Cheng, T; Deo, N; El-Hoss, J; Little, DG; Mikulec, K; Schindeler, A; Sullivan, K | 1 |
Aoki, Y; Inoue, S; Kure, S; Matsubara, Y; Miyagawa-Tomita, S; Moriya, M; Niihori, T; Oba, D; Ogura, T; Ono, M; Watanabe, Y | 1 |
Bachiller, V; Bertin, S; Francés, R; García-Martínez, I; González-Navajas, JM; Herdman, S; Lee, J; Lozano-Ruiz, B; Raz, E; Such, J; Zapater, P | 1 |
Fujita, A; Funakami, Y; Ichida, S; Imano, M; Itoh, T; Nishida, S; Ogawa, N; Sakamoto, K; Satou, T; Shimaoka, H; Suzuyama, N; Takeda, T; Tani, T; Tsubaki, M | 1 |
Cripe, TP; Dombi, E; Dunn, RS; Janhofer, D; Jones, DR; Jousma, E; Kim, MO; Masters, AR; Ratner, N; Rizvi, TA; Wu, J | 1 |
Carlson, SG; Chen, Z; Cheng, H; Coupar, JF; Eytan, DF; Mohan, S; Pierce, ML; Shah, S; Van Waes, C; Vander Broek, R; Zhang, J | 1 |
Dankort, D; Green, S; Juan, J; McMahon, M; Shai, A | 1 |
Awazu, M; Harada, A; Iwasaki, Y; Kohno, M; Kugisaki, S; Ozaki, KI; Tamiya, M; Tanimura, S | 1 |
Atkins, HS; Bryant, C; Clark, GC; D'Elia, RV; Saint, RJ | 1 |
Burga, RA; Fernandes, R; Li, C; Sweeney, EE; Zhu, Y | 1 |
Dawson, J; Esser, RE; Fujimoto, R; Kimble, EF; King, JN; Lees, P; Maniara, W; Marshall, PJ; O'Byrne, L; Quadros, E; Toutain, PL | 1 |
Boulet, J; Brown, W; Butterworth, J; Coupal, M; Delorme, D; Gawell, L; Griffin, AM; Hodzic, L; Jones, P; Labarre, M; Lavoie, R; Roberts, E; Salois, D; St-Onge, S; Walpole, C; Xiao, W | 1 |
Aguirre, S; Collette, W; Huang, W; Ko, M; Marroquin, L; Matsumoto, D; Yang, AH; Younis, HS | 1 |
Bedja, D; Chen, Y; Cohn, RD; Dietz, HC; Doyle, JJ; Habashi, JP; Holm, TM; Judge, DP; Kim, D; Lindsay, ME; Loeys, BL; Marugan, JJ; Patnaik, S; Schoenhoff, F; Thomas, CJ; van Erp, C | 1 |
Anichini, A; Bergamo, P; Biagioni, F; Blandino, G; Cesta Incani, U; Ciuffreda, L; Cognetti, F; De Maria, R; Del Bufalo, D; Desideri, M; Di Sanza, C; Eramo, A; Falcone, I; McCubrey, JA; Milella, M; Orlandi, A; Passeri, D; Ricciardi, MR; Sabapathy, K; Sette, G; Tafuri, A | 1 |
Ke, E; Leblanc, M; Oldfield, E; Shaw, RJ; Verma, IM; Xia, Y; Yeddula, N; Zhang, Y | 1 |
Armbrecht, HJ; Pereira, RC; Perwad, F; Portale, AA; Ranch, D; Zhang, MY | 1 |
Juan, J; McMahon, M; Sweet-Cordero, A; Trejo, CL; Vicent, S | 1 |
Arce-Franco, M; Barreiro, O; Díaz-González, F; Domínguez-Luis, M; Feria, M; Herrera-García, A; López-Fernández, J; Sánchez-Madrid, F | 1 |
Akutagawa, J; Braun, BS; Chang, T; Kogan, S; Krisman, K; Lauchle, JO; Shannon, K; Theobald, EH; Xu, J | 1 |
Lenz, SD | 1 |
Chodorowski, Z | 1 |
Evan, AP; Gardner, KD | 1 |
Bekemeier, H; Hirschelmann, R; Reimann, S; Schobess, B | 1 |
Evan, AP; Fitzgerrel, WW; Gardner, KD; Solomon, S | 1 |
Carlton, WW; Lenz, SD | 1 |
36 other study(ies) available for diphenylamine and Disease Models, Animal
Article | Year |
---|---|
The Mitochondria-Targeted Methylglyoxal Sequestering Compound, MitoGamide, Is Cardioprotective in the Diabetic Heart.
Topics: Amides; Animals; Benzamides; Cardiotonic Agents; Diabetic Cardiomyopathies; Diphenylamine; Disease Models, Animal; Insulin; Male; Mice, Inbred C57BL; Mitochondria, Heart; Mutation; Pyruvaldehyde; Ventricular Function, Left | 2019 |
Modulation of spine fusion with BMP-2, MEK inhibitor (PD0325901), and zoledronic acid in a murine model of NF1 double inactivation.
Topics: Animals; Benzamides; Diphenylamine; Disease Models, Animal; Mice; Mitogen-Activated Protein Kinase Kinases; Neurofibromatosis 1; Zoledronic Acid | 2021 |
Costello syndrome model mice with a Hras
Topics: Animals; Benzamides; Cell Proliferation; Costello Syndrome; Cytokines; Dermatitis, Atopic; Diphenylamine; Disease Models, Animal; Disease Susceptibility; Ear; Epidermis; Inflammation Mediators; Interleukin-33; Male; Mice, Inbred C57BL; Mitogen-Activated Protein Kinase Kinases; Models, Biological; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Pruritus; Pyroglyphidae | 2020 |
Multicomponent synthesis and preliminary anti-inflammatory activity of lipophilic diphenylamines.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Artemia; Cell Survival; Diphenylamine; Disease Models, Animal; Dose-Response Relationship, Drug; Edema; Hydrophobic and Hydrophilic Interactions; Macrophages; Mice; Molecular Structure; RAW 264.7 Cells; Structure-Activity Relationship; Tetradecanoylphorbol Acetate | 2021 |
Apparent Diffusion Coefficient (ADC) predicts therapy response in pancreatic ductal adenocarcinoma.
Topics: Animals; Carcinoma, Pancreatic Ductal; Diffusion Magnetic Resonance Imaging; Diphenylamine; Disease Models, Animal; Humans; Image Processing, Computer-Assisted; MAP Kinase Kinase Kinases; Mice; Neoadjuvant Therapy; Pancreatic Neoplasms; Protein Kinase Inhibitors; Response Evaluation Criteria in Solid Tumors; Sulfonamides | 2017 |
Pharmacologic inhibition of MEK signaling prevents growth of canine hemangiosarcoma.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Proliferation; Diphenylamine; Disease Models, Animal; Dogs; Drug Screening Assays, Antitumor; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Hemangiosarcoma; Humans; Mice; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
NF1 deletion generates multiple subtypes of soft-tissue sarcoma that respond to MEK inhibition.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Proliferation; Diphenylamine; Disease Models, Animal; Gene Deletion; Genes, Neurofibromatosis 1; Humans; MAP Kinase Signaling System; Mice; Mice, Transgenic; Microvessels; Mitogen-Activated Protein Kinase Kinases; Nerve Sheath Neoplasms; Neurofibromin 1; Sarcoma | 2013 |
Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer.
Topics: Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Diphenylamine; Disease Models, Animal; Female; Humans; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Mice; Mice, Inbred NOD; Mice, SCID; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyridones; Pyrimidines; Random Allocation; TOR Serine-Threonine Kinases; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2014 |
Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.
Topics: Animals; Apoptosis; Benzamides; Blotting, Western; Cell Proliferation; Cells, Cultured; Diphenylamine; Disease Models, Animal; Drug Synergism; Everolimus; Fluorescent Antibody Technique; Humans; Immunoenzyme Techniques; Immunosuppressive Agents; Mice; Mice, Transgenic; Mitogen-Activated Protein Kinases; Neoplasm Grading; Neurilemmoma; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Schwann Cells; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2014 |
Discovery of TD-4306, a long-acting β2-agonist for the treatment of asthma and COPD.
Topics: Adrenergic beta-2 Receptor Agonists; Animals; Asthma; Cell Line; Diphenylamine; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Drug Discovery; Guinea Pigs; Humans; Molecular Structure; Pulmonary Disease, Chronic Obstructive; Quinolones; Rats; Receptors, Adrenergic, beta-2; Structure-Activity Relationship | 2014 |
A Combination of rhBMP-2 (Recombinant Human Bone Morphogenetic Protein-2) and MEK (MAP Kinase/ERK Kinase) Inhibitor PD0325901 Increases Bone Formation in a Murine Model of Neurofibromatosis Type I Pseudarthrosis.
Topics: Animals; Benzamides; Bone Morphogenetic Protein 2; Diphenylamine; Disease Models, Animal; Drug Therapy, Combination; Female; Mice; Mitogen-Activated Protein Kinase Kinases; Neurofibromatosis 1; Osteogenesis; Pseudarthrosis; Recombinant Proteins; Transforming Growth Factor beta | 2014 |
New BRAF knockin mice provide a pathogenetic mechanism of developmental defects and a therapeutic approach in cardio-facio-cutaneous syndrome.
Topics: Animals; Benzamides; Benzazepines; Diphenylamine; Disease Models, Animal; Drug Synergism; Ectodermal Dysplasia; Embryo, Mammalian; Facies; Failure to Thrive; Female; Gene Expression Regulation; Gene Knock-In Techniques; Genes, Lethal; Heart Defects, Congenital; Histone Deacetylase Inhibitors; Histone Demethylases; Humans; Liver; Male; MAP Kinase Kinase Kinases; Mice; Mice, Transgenic; Mutation; Myocardium; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrimidines; Signal Transduction; Skull | 2014 |
Dual-specificity phosphatase 6 regulates CD4+ T-cell functions and restrains spontaneous colitis in IL-10-deficient mice.
Topics: Animals; Benzamides; Cell Differentiation; Cell Proliferation; Colitis; Colon; Diphenylamine; Disease Models, Animal; Dual Specificity Phosphatase 6; Gene Expression Regulation; Immunity, Mucosal; Interferon-gamma; Interleukin-10; Interleukin-17; Mice; Mice, Inbred C57BL; Mice, Knockout; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Receptors, Antigen, T-Cell; Signal Transduction; T-Lymphocytes, Regulatory; Th1 Cells | 2015 |
PKC/MEK inhibitors suppress oxaliplatin-induced neuropathy and potentiate the antitumor effects.
Topics: Animals; Benzamides; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Diphenylamine; Disease Models, Animal; Drug Synergism; Hyperalgesia; Male; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Organoplatinum Compounds; Oxaliplatin; Protein Kinase Inhibitors; Spinal Cord; Tamoxifen | 2015 |
Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of Neurofibromatosis type 1.
Topics: Animals; Antineoplastic Agents; Benzamides; Diphenylamine; Disease Models, Animal; Enzyme Inhibitors; Immunohistochemistry; MAP Kinase Kinase Kinases; Mice; Mice, Inbred C57BL; Microscopy, Electron; Neurofibromatosis 1 | 2015 |
MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
Topics: Animals; Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cytokines; Diphenylamine; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression; Genes, Reporter; Head and Neck Neoplasms; Humans; Inflammation Mediators; Mitogen-Activated Protein Kinase Kinases; Morpholines; NF-kappa B; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcriptional Activation; Triazines; Xenograft Model Antitumor Assays | 2015 |
TP53 Silencing Bypasses Growth Arrest of BRAFV600E-Induced Lung Tumor Cells in a Two-Switch Model of Lung Tumorigenesis.
Topics: Adenocarcinoma; Adenoma; Animals; Benzamides; Cell Cycle Checkpoints; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p16; Diphenylamine; Disease Models, Animal; Gene Expression Regulation, Neoplastic; Gene Silencing; Lung Neoplasms; MAP Kinase Kinase Kinases; Mice, Transgenic; Proto-Oncogene Proteins B-raf; Tumor Suppressor Protein p53 | 2015 |
Targeting the ERK signaling pathway as a potential treatment for insulin resistance and type 2 diabetes.
Topics: 3T3-L1 Cells; Adipocytes; Adipokines; Adiponectin; Animals; Benzamides; Blood Glucose; Chemokine CCL2; Diabetes Mellitus, Type 2; Diet, High-Fat; Diphenylamine; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Fatty Acids, Nonesterified; Glucose Tolerance Test; Hyperlipidemias; Immunoblotting; In Vitro Techniques; Insulin; Insulin Resistance; Interleukin-6; Lipolysis; Male; MAP Kinase Signaling System; Mice; Protein Kinase Inhibitors; Real-Time Polymerase Chain Reaction; Receptors, Leptin; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Triglycerides; Tumor Necrosis Factor-alpha | 2016 |
Mitogen-activated protein kinases (MAPKs) are modulated during Francisella tularensis infection, but inhibition of extracellular-signal-regulated kinases (ERKs) is of limited therapeutic benefit.
Topics: Animals; Bacterial Load; Benzamides; Cell Line; Cytokines; Diphenylamine; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression Profiling; Host-Pathogen Interactions; Liver; Macrophages, Alveolar; Mice, Inbred BALB C; Protein Kinase Inhibitors; Spleen; Treatment Outcome; Tularemia | 2016 |
Photothermal therapy improves the efficacy of a MEK inhibitor in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
Topics: Animals; Benzamides; Cell Line, Tumor; Diphenylamine; Disease Models, Animal; Drug Screening Assays, Antitumor; Extracellular Signal-Regulated MAP Kinases; Ferrocyanides; Hyperthermia, Induced; Infrared Rays; Laser Therapy; MAP Kinase Kinase Kinases; Mice; Nanoparticles; Neoplasm Proteins; Neurilemmoma; Neurofibromatosis 1; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Surface Plasmon Resonance | 2016 |
Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase-2.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Cell Line; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diphenylamine; Disease Models, Animal; Edema; Fever; Humans; Isoenzymes; Male; Pain; Phenylacetates; Protein Binding; Random Allocation; Rats; Rats, Inbred Lew; Rats, Sprague-Dawley; Rats, Wistar | 2009 |
N,N-Diethyl-4-[(3-hydroxyphenyl)(piperidin-4-yl)amino] benzamide derivatives: the development of diaryl amino piperidines as potent delta opioid receptor agonists with in vivo anti-nociceptive activity in rodent models.
Topics: Analgesics; Animals; Benzamides; Diphenylamine; Disease Models, Animal; Mice; Piperidines; Rats; Receptors, Opioid, delta; Structure-Activity Relationship | 2009 |
PD0325901, a mitogen-activated protein kinase kinase inhibitor, produces ocular toxicity in a rabbit animal model of retinal vein occlusion.
Topics: Administration, Oral; Animals; Antigens, CD; Benzamides; Cells, Cultured; Diphenylamine; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelial Protein C Receptor; Endothelium, Vascular; Female; Fluorescein Angiography; Gene Expression Regulation; Humans; Male; Microarray Analysis; Mitogen-Activated Protein Kinase Kinases; Oxidative Stress; Protein Kinase Inhibitors; Rabbits; Rats; Rats, Inbred BN; Receptors, Cell Surface; Retinal Vein Occlusion; Species Specificity; Umbilical Veins | 2009 |
Noncanonical TGFβ signaling contributes to aortic aneurysm progression in Marfan syndrome mice.
Topics: Animals; Anthracenes; Aorta; Aortic Aneurysm; Diphenylamine; Disease Models, Animal; Disease Progression; Enzyme Activation; Losartan; MAP Kinase Signaling System; Marfan Syndrome; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinase 8; Protein Kinase Inhibitors; Smad2 Protein; Smad4 Protein; Sulfonamides; Transforming Growth Factor beta | 2011 |
The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms.
Topics: Animals; Benzamides; Diphenylamine; Disease Models, Animal; Enzyme Activation; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Melanoma; Mice; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; PTEN Phosphohydrolase; Signal Transduction | 2012 |
Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model.
Topics: Animals; Benzamides; Cell Line, Tumor; Cell Proliferation; Diphenylamine; Disease Models, Animal; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; I-kappa B Kinase; Kaplan-Meier Estimate; Lung Neoplasms; Male; MAP Kinase Signaling System; Mice; Mice, Knockout; Mice, Nude; Oligonucleotide Array Sequence Analysis; Proto-Oncogene Proteins p21(ras); Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Tetraspanin 30; Tissue Inhibitor of Metalloproteinase-1; Tumor Burden | 2012 |
Chronic inhibition of ERK1/2 signaling improves disordered bone and mineral metabolism in hypophosphatemic (Hyp) mice.
Topics: Animals; Benzamides; Bone and Bones; Bone Diseases; Diphenylamine; Disease Models, Animal; Enzyme Inhibitors; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Hypophosphatemia; Male; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Minerals; Mitogen-Activated Protein Kinase Kinases; Mutation; PHEX Phosphate Regulating Neutral Endopeptidase; Phosphates; Signal Transduction; Vitamin D | 2012 |
MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Diphenylamine; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Lung Neoplasms; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Mice; Mice, Transgenic; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Respiratory Mucosa; Tumor Cells, Cultured | 2012 |
In vivo modulation of the inflammatory response by nonsteroidal antiinflammatory drug-related compounds that trigger L-selectin shedding.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Line; Cyclooxygenase 1; Diphenylamine; Disease Models, Animal; Human Umbilical Vein Endothelial Cells; Humans; Inflammation; L-Selectin; Leukocyte Count; Leukocyte Rolling; Male; Mice; Mice, Inbred Strains; Neutrophils | 2013 |
Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.
Topics: Animals; Benzamides; Cell Differentiation; Cell Proliferation; Child; Child, Preschool; Diphenylamine; Disease Models, Animal; Erythropoiesis; Hematopoiesis, Extramedullary; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myelomonocytic, Juvenile; Mice; Mice, Mutant Strains; Mitogen-Activated Protein Kinase Kinases; Neurofibromatosis 1; Neurofibromin 1 | 2013 |
Investigation of regional glutathione levels in a model of chemically-induced renal papillary necrosis.
Topics: Animals; Body Weight; Cricetinae; Diphenylamine; Disease Models, Animal; Glutathione; Kidney; Kidney Medulla; Kidney Papillary Necrosis; Male; Mesocricetus; Organ Size | 1996 |
[Experimental cystic renal degeneration].
Topics: Animals; Basement Membrane; Diphenylamine; Disease Models, Animal; Female; Maternal-Fetal Exchange; Polycystic Kidney Diseases; Pregnancy; Rats | 1978 |
Comparison of human polycystic and medullary cystic kidney disease with diphenylamine-induced cystic disease.
Topics: Aniline Compounds; Animals; Basement Membrane; Diphenylamine; Disease Models, Animal; Humans; Kidney; Kidney Diseases, Cystic; Kidney Glomerulus; Kidney Tubules; Male; Microscopy, Electron, Scanning; Polycystic Kidney Diseases; Rats | 1976 |
6-Sulfanilamidoindazole arthritis: influence of alloxan diabetes, phenylbutazone and D-penicillamine on inflammatory size, sulfhydryl groups, diphenylamine reaction and enzymes of the serum.
Topics: Alkaline Phosphatase; Animals; Arthritis; Blood Glucose; Diabetes Mellitus, Experimental; Diphenylamine; Disease Models, Animal; Indazoles; Male; Muramidase; Penicillamine; Phenylbutazone; Pyrazoles; Rats; Sulfanilamides; Sulfhydryl Compounds | 1975 |
Function and structure in the diphenylamine-exposed kidney.
Topics: Aniline Compounds; Animals; Body Fluids; Body Weight; Diphenylamine; Disease Models, Animal; Glomerular Filtration Rate; Hydrostatic Pressure; Inulin; Kidney Cortex; Kidney Diseases, Cystic; Kidney Tubules; Loop of Henle; Male; Nephrons; Oils; Rats | 1976 |
Diphenylamine-induced renal papillary necrosis and necrosis of the pars recta in laboratory rodents.
Topics: Aniline Compounds; Animals; Cricetinae; Diphenylamine; Disease Models, Animal; Gerbillinae; Kidney; Kidney Papillary Necrosis; Male; Mesocricetus; Rats; Rats, Inbred Strains; Rodent Diseases; Spleen | 1990 |